All In Biotech

Drug Trial Radar · NCT03693612

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Nov 26, 2018

Primary completion

Jun 25, 2021

Study completion Sep 16, 2021

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
MedImmune LLC
First posted
Oct 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous Cell Carcinomas (HNSCC) to warrant further clinical investigation (Part 2). Part 1 (dose escalation) will enroll subjects with advanced, selected solid tumors. Subjects will receive escalating doses of GSK3359609 and tremelimumab in combination in Part 1. Part 2 is randomized expansion and will enroll subjects with R/R HNSCC who have disease progression after receiving at least 1 platinum-based chemotherapy and at least 1 anti-programmed death receptor protein-1 (PD-1)/anti-programmed death-ligand 1 (PD-L1) therapy, whether in combination or separately. In Part 2, subjects will be randomized in a ratio of 2:1 to receive either GSK3359609 in combination with tremelimumab at the recommended Phase 2 dose or investigators choice of a single-agent standard of care (SOC) therapy including paclitaxel, docetaxel or cetuximab. The total duration of subjects in the study will be approximately 4 years.

Conditions

  • Neoplasms

Interventions

  • feladilimabDrug

    feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.

  • TremelimumabDrug

    Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .

  • DocetaxelDrug

    Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m\^2).

  • PaclitaxelDrug

    Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m\^2.

  • CetuximabDrug

    Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m\^2 followed by 250 mg/m\^2 once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs)-Part 1Time frame: Up to 28 days
  2. Number of Participants With DLTs According to Severity-Part 1Time frame: Up to 28 days
  3. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)-Part 1Time frame: Up to 4 years
  4. Number of Participant With AE/SAE/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1Time frame: Up to 4 years
  5. Number of Participants With AEs, SAEs, AESIs According to Severity - Part 1Time frame: Up to 4 years
  6. Number of Participants With Severe- AEs/SAEs/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1Time frame: Up to 4 years
  7. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)-Part 1Time frame: Baseline (Day 1) and Week 4
  8. Change From Baseline in Temperature-Part 1Time frame: Baseline (Day 1) and Week 4
  9. Change From Baseline in Pulse Rate-Part 1Time frame: Baseline (Day 1) and Week 4
  10. Change From Baseline in Respiratory Rate-Part 1Time frame: Baseline (Day 1) and Week 4
  11. Change From Baseline in Oxygen Saturation-Part 1Time frame: Baseline (Day 1) and Week 4
  12. Number of Participants With Electrocardiogram (ECG) FindingsTime frame: Baseline (Pre dose, Day 1) and up to 4 Years
  13. Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count-Part 1Time frame: Baseline (Day 1) and Week 4
  14. Change From Baseline in Hemoglobin Level-Part 1Time frame: Baseline (Day 1) and Week 4
  15. Change From Baseline in Hematocrit Level-Part 1Time frame: Baseline (Day 1) and Week 4
  16. Change From Baseline in Erythrocytes Count-Part 1Time frame: Baseline (Day 1) and Week 4
  17. Change From Baseline in Albumin and Total Protein Levels-Part 1Time frame: Baseline (Day 1) and Week 4
  18. Change From Baseline in Creatinine and Bilirubin Levels-Part 1Time frame: Baseline (Day 1) and Week 4
  19. Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Lactate Dehydrogenase (LDH) Levels-Part 1Time frame: Baseline (Day 1) and Week 4
  20. Change From Baseline in Amylase and Lipase Levels-Part 1Time frame: Baseline (Day 1) and week 4
  21. Change From Baseline in Urea, Glucose, Potassium, Sodium and Calcium Levels-Part 1Time frame: Baseline (Day 1) and Week 4
  22. Change From Baseline in Specific Gravity of Urine-Part 1Time frame: Baseline (Day 1) and Week 4
  23. Change From Baseline in Potential of Hydrogen (pH) of Urine-Part 1Time frame: Baseline (Day 1) and Week 4
  24. Number of Participants With Abnormal Urinalysis Parameters-Part 1Time frame: Week 4
  25. Change From Baseline in Thyroid Stimulating Hormone (TSH) or Thyrotropin-Part 1Time frame: Baseline (Day 1) and Week 4
  26. Change From Baseline in Free Triiodothyronine (T3)-Part 1Time frame: Baseline (Day 1) and Week 4
  27. Change From Baseline in Free Thyroxine (T4)-Part 1Time frame: Baseline (Day 1) and Week 4
  28. Overall Survival-Part 2Time frame: Up to 4 years

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.